Primary endpoints:1
- ZOE-50: to evaluate the efficacy of SHINGRIX vs. placebo in reducing the risk of shingles in subjects ≥50 years old
- ZOE-70: to evaluate the efficacy of SHINGRIX vs. placebo in reducing the risk of shingles in subjects ≥70 years old
- The pooled analysis of ZOE-50 and ZOE-70: to evaluate the efficacy of the vaccine vs. placebo in reducing the risk of shingles and the incidence of PHN in the overall population of subjects ≥70 years old from both studies
Secondary endpoint:3
- To evaluate the safety and reactogenicity of the vaccine